DrugPatentWatch Database Preview
Eli Lilly And Co Company Profile
What is the competitive landscape for ELI LILLY AND CO, and when can generic versions of ELI LILLY AND CO drugs launch?
ELI LILLY AND CO has seven approved drugs.
There are fifteen US patents protecting ELI LILLY AND CO drugs.
There are two hundred and eighteen patent family members on ELI LILLY AND CO drugs in fifty-one countries and sixty-four supplementary protection certificates in thirteen countries.
Summary for Eli Lilly And Co
| International Patents: | 218 |
| US Patents: | 15 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 7 |
| Drug Master File Entries: | 37 |
| Patent Litigation for Eli Lilly And Co: | See patent lawsuits for Eli Lilly And Co |
| PTAB Cases with Eli Lilly And Co as patent owner: | See PTAB cases with Eli Lilly And Co as patent owner |
Drugs and US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-002 | Sep 28, 2017 | RX | Yes | No | 7,855,211 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-003 | Sep 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Eli Lilly And Co | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-002 | Jul 10, 2009 | AB | RX | Yes | Yes | 8,569,325*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-001 | Sep 28, 2017 | RX | Yes | No | 7,855,211 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Eli Lilly And Co | VERZENIO | abemaciclib | TABLET;ORAL | 208716-002 | Sep 28, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Eli Lilly And Co
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-008 | Jul 6, 2000 | 4,971,998*PED | ➤ Sign Up |
| Eli Lilly And Co | PROZAC | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-001 | Dec 29, 1987 | 4,018,895 | ➤ Sign Up |
| Eli Lilly And Co | AXIRON | testosterone | SOLUTION, METERED;TRANSDERMAL | 022504-001 | Nov 23, 2010 | 8,071,075 | ➤ Sign Up |
| Eli Lilly And Co | EFFIENT | prasugrel hydrochloride | TABLET;ORAL | 022307-001 | Jul 10, 2009 | 5,288,726*PED | ➤ Sign Up |
| Eli Lilly And Co | SARAFEM | fluoxetine hydrochloride | CAPSULE;ORAL | 018936-007 | Jul 6, 2000 | 4,971,998*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ELI LILLY AND CO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Topical Solution | 30 mg/1.5 mL | ➤ Subscribe | 2013-01-29 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2013-07-10 |
Non-Orange Book US Patents for Eli Lilly And Co
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,906,028 | Stable insulin formulations | ➤ Sign Up |
| 7,427,275 | Medication dispensing apparatus with triple screw threads for mechanical advantage | ➤ Sign Up |
| 8,177,449 | Spreading implement | ➤ Sign Up |
| 8,357,393 | Transdermal delivery rate control using amorphous pharmaceutical compositions | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Eli Lilly And Co Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 100531813 | ➤ Sign Up |
| Colombia | 6382125 | ➤ Sign Up |
| Morocco | 32903 | ➤ Sign Up |
| Norway | 20032902 | ➤ Sign Up |
| South Korea | 20010013700 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Eli Lilly And Co Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00698 | Netherlands | ➤ Sign Up | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| 2107069/02 | Switzerland | ➤ Sign Up | PRODUCT NAME: INSULIN DEGLUDEC + INSULIN ASPART; REGISTRATION NO/DATE: SWISSMEDIC 62648 12.09.2013 |
| 0880 | Netherlands | ➤ Sign Up | PRODUCT NAME: SNELWERKENDE INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109 |
| 226 | Luxembourg | ➤ Sign Up | PRODUCT NAME: COMBINATION D'INSULINE DEGLUDEC ET INSULINE ASPARTE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION DATE: 20130121 |
| C/GB00/027 | United Kingdom | ➤ Sign Up | PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
